These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1485836)

  • 1. [Pharmacokinetics of hypolipedemic agents. 9. The question of biliary excretion of the hypolipidemic agent ciprofibrate (1) (2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-2-methylpropionic acid].
    Oelschläger H; Rothley D; Schröder D; Scherm S
    Arch Pharm (Weinheim); 1992 Nov; 325(11):701-4. PubMed ID: 1485836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
    Oelschläger H; Rothley D; Schmidt W
    Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
    [No Abstract]   [Full Text] [Related]  

  • 4. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Conjugation reactions of ciprofibrate with human and laboratory animals].
    Oelschläger H; Müller D; Hellwich KH; Ueberall S; Seeling A; Machts H; Hofmann B; Glöckner R
    Arzneimittelforschung; 2003; 53(4):247-53. PubMed ID: 12785120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
    Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
    Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.
    Chianale J; Vollrath V; Wielandt AM; Amigo L; Rigotti A; Nervi F; Gonzalez S; Andrade L; Pizarro M; Accatino L
    Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):781-6. PubMed ID: 8615769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of clofibrate and tiadenol on the elimination of lipids and bile acids in rat bile.
    Cuchet P; Morrier C; Cand F; Keriel C
    Lipids; 1981 Oct; 16(10):732-8. PubMed ID: 7300592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemfibrozil--the effect of biliary cholesterol saturation of a new lipid-lowering agent and its comparison with clofibrate.
    Hall MJ; Nelson LM; Russell RI; Howard AN
    Atherosclerosis; 1981 Jul; 39(4):511-6. PubMed ID: 6942844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drug.
    Arnold A; McAuliff JP; Powers LG; Phillips DK; Beyler AL
    Atherosclerosis; 1979 Feb; 32(2):155-63. PubMed ID: 454514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
    Arnold A; McAuliff MP; Beyler AL
    J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Action of tiadenol and clofibrate on biliary excretions of cholesterol and bile salts in rats.
    Fredj G; Clenet M; Cuchet P; Rousselet F; Rozé C
    Digestion; 1979; 19(4):228-36. PubMed ID: 478204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of tiadenol, clofibrate and clofibride on bile composition in the rat.
    Rozé C; Cuchet P; Souchard M; Vaille C; Debray C
    Eur J Pharmacol; 1977 May; 43(1):57-64. PubMed ID: 862664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of thioridazine or chlorpromazine on increased hepatic NAD+ level in rats fed clofibrate, a hypolipidaemic drug.
    Shin M; Asada S; Mizumori N; Sano K; Umezawa C
    J Pharm Pharmacol; 1998 Apr; 50(4):431-6. PubMed ID: 9625489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of fibric acid derivatives (fibrates).
    Miller DB; Spence JD
    Clin Pharmacokinet; 1998 Feb; 34(2):155-62. PubMed ID: 9515185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia.
    Angelin B; Einarsson K; Leijd B
    Eur J Clin Invest; 1984 Feb; 14(1):73-8. PubMed ID: 6421601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gemfibrozil administration on biliary lipid secretion in hyperlipidemic patients. A crossover study with clofibrate.
    Mazzella G; Bazzoli F; Villanova N; Simoni P; Festi D; Roda A; Aldini R; Roda E
    Scand J Gastroenterol; 1990 Dec; 25(12):1227-34. PubMed ID: 2274744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment.
    Raedsch R; Plachky J; Wolf N; Simonis G
    Eur J Drug Metab Pharmacokinet; 1995; 20(2):113-8. PubMed ID: 8582435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of clinofibrate, a new hypolipidemic agent, on biliary and serum lipids in patients with hyperlipidemia.
    Takeuchi N; Kukita H; Kajiyama G; Fujiyama M; Ishikawa K; Miki H; Mishima T; Murata K; Asano T
    Atherosclerosis; 1982 Apr; 42(2-3):129-39. PubMed ID: 7073798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of route of administration and biliary excretion on the pharmacokinetics of isotretinoin in the dog.
    Cotler S; Chen S; Macasieb T; Colburn WA
    Drug Metab Dispos; 1984; 12(2):143-7. PubMed ID: 6144477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.